Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Lorbrena
(Canada) [Available]Synonyms :
relatlimab
Class :
Antineoplastic agents Subclass, Plastic lymphoma kinase inhibitor
Brand Name :
Lorbrena
(Canada) [Available]Synonyms :
relatlimab
Class :
Antineoplastic agents Subclass, Plastic lymphoma kinase inhibitor
Dosage Forms & Strengths Â
Tablet Â
25 mg Â
100 mg Â
Indicated for NSCLC, metastatic non-small cell lung cancer in those patients who have tumors of anaplastic lymphoma kinase (ALK)-positive
100 mg orally each day with/without food
Continue until unacceptable toxicity or disease
Dose Adjustments
In case of adverse reactions:
1st dose reduction: 75 mg each day
2nd dose reduction: 50 mg each day
If unable to tolerate the dose of 50 mg per day: permanently discontinue the medication
In case of effects on central nervous system:
1st grade: Continue the same dose until recovery to baseline; start over at the same or decreased dose
2nd or 3rd grade: Pause the dose until less than first grade; start over at reduced dose
4th grade: permanently discontinue the medication
Non-Small Cell Lung Cancer  Â
Take a dose of 100 mg orally daily Â
Not determined Â
lorlatinib: they may increase the hepatotoxic effect of CYP3A4 Inducers
lorlatinib: they may increase the hepatotoxic effect of CYP3A4 Inducers
lorlatinib: they may increase the hepatotoxic effect of CYP3A4 Inducers
lorlatinib: they may increase the hepatotoxic effect of CYP3A4 Inducers
lorlatinib: they may increase the hepatotoxic effect of CYP3A4 Inducers
When naficillin combines with lorlatinib, nafcillin will decrease the effect of action of lorlatinib by affecting enzyme CYP3A4 metabolism.
when both drugs are combined, there may be a decreased effect of lorlatinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
the effect of abametapir is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of abemaciclib is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of alfentanil is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of alpelisib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of apalutamide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of armodafinil is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of atazanivir is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of avanafil is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of avapritinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of axitinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of bedaquiline is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the level of effect of lorlatinib will decrease by MDR1 P-glycoprotein efflux transporter due to berotralsat
the level of effect of lorlatinib will decrease by MDR1 P-glycoprotein efflux transporter due to istradefylline
the effect of bosutinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of brigatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of capmatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of carbamazepine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of caripazine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of chloramphenicol is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism. the effect of carbamazepine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of clarithromycin is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of clobazam is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of cobicistat is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of cobimetinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of conivaptan is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of conjugated estrogens is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of cyclosporine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of dabrafenib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of daclatasvir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of daridorexant is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of darunavir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of deflazacort is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of delavirdine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of diltiazem is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of doxorubicin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of doxorubicin liposomal is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of efavirenz is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of elbasvir and grazoprevir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of elbasvir and grazoprevir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of encorafenib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of entrectinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of enzalutamide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of erdafitinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ergotamine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of erlotinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of eslicarbazepine acetate is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
estrogens conjugated synthetic
the effect of carbamazepine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of estrogens esterified is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of etravirine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of fentanyl is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of fexinidazole is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of finerenone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of flibanserin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of fosamprenavir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ganaxolone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of glasdegib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of grapefruit is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of guanfacine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of idelasilib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of imatinib is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of indinavir is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of infigratinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of isoniazid is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of istradefylline is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of itraconazole is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ketoconazole is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of imatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of imatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of imatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of levoketoconazole is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of levonorgestrel is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of levonorgestrel oral is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of linagliptin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of lopinavir is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of lumacaftor/ivacaftor is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of lumateperone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of lurasidone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of lurbinectedin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of medroxyprogesterone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of mestranol is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of midazolam is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of mifepristone is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of mobocertinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of modafinil is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of nefazodone is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of nelfinavir is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of nevirapine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of nisoldipine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of norethindrone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of norgestrel is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of olaparib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ombitasvir/paritaprevir/ritonavir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ombitasvir/paritaprevir/ritonavir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ombitasvir/paritaprevir/ritonavir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of pemigatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of pexidartinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of pimavanserin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of pimozide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of posaconazole is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of pralsetinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of pretomanid is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of progesterone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of quinidine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of quinine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ranolazine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of rifabutin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of rimegepant is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of norgestrel is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of selpercatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of selumetinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of siponimod is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of sirolimus is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of sofosbuvir/velpatisivir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of sofosbuvir/velpatisivir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of sonidegib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of stiripentol is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of tacrolimus is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of telotristat is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of tipranavir is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of triazolam is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ubrogepant is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ulipristal is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of upadacitinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of venetoclax is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of vincristine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of vincristine liposomal is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of voclosporin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of vonoprazan is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of vorapaxar is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of voriconazole is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of voxelotor is decreased by lorlatinib, by altering intestinal or hepatc CYP3A4 enzyme metabolism
the effect of voxilaprevir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of zanubrutinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased metabolism of alpelisib   
CYP3A enhancers (strong) may enhance the hepatotoxic effect of lorlatinib CYP3A strong enhancers of the small intestine may reduce the bioavailability of lorlatinib
relugolix/​estradiol/​norethindroneÂ
may diminish the effects of each other by pharmacodynamic antagonism
the effect of abiraterone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of acalabrutinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of alfuzosin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of alprazolam is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of amiodarone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of amlodipine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of apixaban is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of apremilast is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of aprepitant is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of aripiprazole is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of artemether/lumefantriine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of artemether/lumefantriine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of atogepant is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of atorvastatin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of belumosudil is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of benzhydrococodone/acetaminophen is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of bortezomib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of bosentan is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of bromocriptine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of buprenorphine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of buprenorphine transdermal is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of buspirone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of cabozantinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of calcitriol is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of cenobamate is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of chlordiazepoxide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of chloroquine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of cilostazol is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of citalopram is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of clonazepam is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of copanlisib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of crizotinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of dantrolene is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of dapsone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of darifenacin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of dasatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of dexamethasone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of diazepam is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of diazepam intranasal is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of disopyramide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of docetaxel is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of doravirine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of dronabinol is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of dronedarone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of duvelisib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of elagolix is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of eliglustat is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of elvitegravir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of eplerenone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of erythromycin base is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of erythromycin ethylsuccinate is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of erythromycin lactobionate is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of erythromycin stearate is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of erythromycin stearate is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of eszopiclone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ethinylestradiol is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ethosuximide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of etoposide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of everolimus is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of exemestane is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of felbamate is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of felodipine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of fentanyl intranasal is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of fentanyl transdermal is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of fentanyl transmucosal is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of flurazepam is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of fostamatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
gefitinib: the effect of gefitinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of glecaprevir/pibrentasvir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of glecaprevir/pibrentasvir is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of haloperidol is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of hydrocodone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of hydroxyprogesterone caproate is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ibrutinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of isofamide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of irinotecan is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of irinotecan liposomal is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of isavuconazonium sulfate is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of isosorbide dinitrate is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of isosorbide mononitrate is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of isradipine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ivosedinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ixabepilone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ixazomib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of lansoprazole is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of lapatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of levamlodipine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of lomitapide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of losartan is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of lovastatin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of maraviroc is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of marijuana is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of mefloquine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of methadone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
methylprednisolone: the effect of methylprednisolone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of midazolam intranasal is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of midostaurin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of mirtazapine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of naldemedine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of naloxegol is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of netupitant/palonosetron is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of netupitant/palonosetron is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of nicardipine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of nifedipine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of nilotinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of nimodipine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of oliceridine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ondansetron is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of osilodrostat is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of osimertinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ospemifene is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of oxycodone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of paclitaxel is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of paclitaxel protein bound is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of palbociclib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of panobinostat is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of pazopanib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of perampanel is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of pitolisant is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of polatuzumab vedotin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ponatinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of praziquantel is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of isradipine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of quetiapine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of regorafenib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of repaglinide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ribociclib is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolismlorl
the effect of riociguat is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ripretinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of rivaroxaban is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of roflumilast is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of rolapitant is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of romidepsin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of sildenafil is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of simvastatin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of solifenacin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of sufentanil is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of sufentanil SL is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of sunitinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of suvorexant is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of tamoxifen is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of tamsulosin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of tasimelteon is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of tazemetostat is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of temsirolimus is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of teniposide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of terbinafine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of tetracycline is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of tezacaftor is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of tiagabine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of ticagrelor is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of tofacitinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of tolvaptan is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of toremifene is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of trabectedin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of tramadol is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of trazodone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of valbenazine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of vandetanib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of vemurafenib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of verapamil is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of vortioxetine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of warfarin is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of zolpidem is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may diminish the concentration of serum when combined with acetaminophen
lorlatinib: they may diminish the serum concentration of acetaminophen
lorlatinib decreases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
lorlatinib decreases the effect of gefitinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
lorlatinib decreases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
may enhance the serum concentration of acetaminophen
may diminish the serum concentration when combined
Actions and spectrum:Â Â
It inhibits the activity of tyrosine kinase receptors those are overactive or mutated in cancer cells which leads to uncontrolled cell growth and proliferation. Â
It may help to slow or stop the growth of cancer cells which causes tumor shrinkage and increase survival rates.Â
Frequency defined Â
>10%  Â
Upper respiratory tract infectionÂ
Pyrexia Â
Vomiting Â
Dizziness  Â
Myalgia Â
NauseaÂ
Cough Â
Headache Â
DiarrheaÂ
Mood effectsÂ
Arthralgia Â
Thrombocytopenia Â
Weight gain Â
Fatigue  Â
Peripheral neuropathy Â
Anemia Â
Hyperglycemia Â
Edema Â
Hypertriglyceridemia Â
1-10%Â Â
Respiratory failureÂ
Mental status changes Â
PyrexiaÂ
DyspneaÂ
Pneumonia Â
Hallucinations Â
<1%Â Â
Vision disorder Â
Headache Â
Dizziness Â
Speech effects Â
Nausea Â
Back pain Â
ArthralgiaÂ
Black box warning Â
None Â
Contraindications and cautions:Â
Contraindications:Â Â
Caution:Â Â
Pregnancy Warnings:Â
Pregnancy category: N/AÂ
Lactation: Excretion of the drug into the human breast milk is unknownÂ
Pregnancy categories:Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.Â
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology:Â Â
lorlatinib is a tyrosine kinase inhibitor which targets several other tyrosine kinase receptors including anaplastic lymphoma kinase and insulin-like growth factor 1 receptor. Â
Pharmacodynamics:Â Â
It interacts with tyrosine kinase receptors, which are important signaling molecules that regulate cellular growth, survival, and differentiation. Â
Pharmacokinetics:Â Â Â
Absorption Â
The peak plasma level is achieved within 1.2 hours.Â
Distribution Â
The volume of distribution achieved during a steady state is 305 L.Â
Metabolism Â
The drug undergoes metabolism in liver.Â
Elimination and Excretion  Â
It is excreted in urine and feces. Â
Administration Â
It is taken orally. Â
Generic Name: Lorlatinib Â
Pronounced: lor-LAT-i-nibÂ
Why do we use Lorlatinib?Â
Lorlatinib is used to treat metastatic non-small cell lung cancer (NSCLC) that tests positive for anaplastic lymphoma kinase (ALK) gene rearrangements. It works by targeting and inhibiting the ALK protein to help stop cancer growth.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
